2 weeks Ago By Defense World Staff
Brandes Investment Partners LP grew its stake in shares of Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ) by 1.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,945,967 shares of the company’s stock after buying an additional 36,944 shares during the period.
Brandes Investment Partners LP owned 0.60% of Elanco Animal Health worth $42,445,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also made changes to their positions in ELAN.
Quarry LP purchased a new stake in Elanco Animal Health during the second quarter valued at about $40,000. Creative Planning increased its position in Elanco Animal Health by 7.9% during the 2nd quarter.
Creative Planning now owns 52,177 shares of the company’s stock worth $753,000 after purchasing an additional 3,801 shares in the last quarter. Algert Global LLC increased its position in Elanco Animal Health by 22.6% during the 2nd quarter.
Algert Global LLC now owns 262,298 shares of the company’s stock worth $3,785,000 after purchasing an additional 48,358 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new position in Elanco Animal Health in the second quarter valued at approximately $2,561,000. Finally, The Manufacturers Life Insurance Company lifted its position in Elanco Animal Health by 11.
3% during the second quarter. The Manufacturers Life Insurance Company now owns 5,990,546 shares of the company’s stock valued at $86,444,000 after buying an additional 609,194 shares in the last quarter. 97.
48% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several brokerages recently issued reports on ELAN. Barclays increased their price target on Elanco Animal Health from $21.
00 to $22.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $20.
00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $17.00 to $15.
00 in a research report on Thursday, September 19th. Finally, Piper Sandler lowered their price objective on shares of Elanco Animal Health from $19.00 to $16.
00 and set a “neutral” rating for the company in a research report on Monday, July 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.
43. Elanco Animal Health Stock Performance Shares of ELAN opened at $14.32 on Monday.
The stock has a market capitalization of $7.08 billion, a PE ratio of -5.40, a price-to-earnings-growth ratio of 1.
33 and a beta of 1.40. The business’s fifty day moving average price is $14.
05 and its 200 day moving average price is $15.07. The company has a debt-to-equity ratio of 0.
92, a current ratio of 2.93 and a quick ratio of 1.75.
Elanco Animal Health Incorporated has a 12-month low of $8.52 and a 12-month high of $18.80.
Elanco Animal Health ( NYSE:ELAN – Get Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.
24 by $0.06. The business had revenue of $1.
18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a negative net margin of 27.
94% and a positive return on equity of 7.29%. The company’s quarterly revenue was up 12.
0% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS.
Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year. Insider Buying and Selling In related news, CEO Jeffrey N.
Simmons acquired 100,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.
00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link .
In other news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $13.
01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Also, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd.
The shares were acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00.
Following the acquisition, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The disclosure for this purchase can be found here .
Company insiders own 0.57% of the company’s stock. Elanco Animal Health Profile ( Free Report ) Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. See Also Five stocks we like better than Elanco Animal Health Do ETFs Pay Dividends? What You Need to Know 3 Bargain Stocks Under $20 With Major Growth Potential Golden Cross Stocks: Pattern, Examples and Charts Top 5 ETFs to Own Now and Into 2025 How Investors Can Identify and Successfully Trade Gap-Down Stocks Watch These 3 Former Short-Squeeze Stocks for a Big Rally Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
